UWM
OTLK icon

Urban Wealth Management’s Outlook Therapeutics OTLK Stock Holding History

Urban Wealth Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$8K Buy
+374
New +$10.8K 0.03% 216

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
VF
Vista Finance Clayton, Missouri $179M AUM 18.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Urban Wealth Management's OTLK Position: Q2 2022 in Review

Urban Wealth Management opened a new position in Outlook Therapeutics (OTLK) in Q2 2022: 374 shares worth $8K. The stake represents 0.03% of the portfolio and ranks #216 among its holdings.

75 funds tracked by Wall St. Rank hold OTLK as of Q2 2022.

  • Urban Wealth Management held 374 shares of Outlook Therapeutics worth $8K as of Q2 2022.
  • Outlook Therapeutics was a new Urban Wealth Management position in Q2 2022.
  • Outlook Therapeutics made up 0.03% of Urban Wealth Management's portfolio in Q2 2022, its #216 holding.
  • 75 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2022.

Based on Urban Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.